A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long term safety of flexible doses (50 to 150 mg
equivalent) of paliperidone palmitate in the treatment of patients with schizophrenia and to
document the pharmacokinetics of paliperidone following fixed multiple intramuscular
injections of paliperidone palmitate 150 mg eq.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.